Enmetazobactam

CHEMBL4458276 Phase 4 Đã phê duyệt Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

314.3 g/mol

LogP

-0.6

Phase

4

This medication protects certain antibiotics from being broken down by bacterial enzymes called beta-lactamases, allowing the antibiotic to work effectively. It is given in combination with an antibiotic to treat resistant bacterial infections.

Khối lượng phân tử

314,3200 g/mol

LogP

-0,60

TPSA

125,00 Å²

Lipinski RO5

Đạt

Cơ chế tác dụng

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

Cấu trúc 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C[n+]1ccn(C[C@@]2(C)[C@H](C(=O)[O-])N3C(=O)C[C@H]3S2(=O)=O)n1

InChI

InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1

Molecular Formula

C11H14N4O5S

HBD / HBA

- / 6

Liên kết có thể quay

2

Nguyên tử nặng

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This medication protects certain antibiotics from being broken down by bacterial enzymes called beta-lactamases, allowing the antibiotic to work effectively. It is given in combination with an antibiotic to treat resistant bacterial infections.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Enmetazobactam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4458276. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23653540. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Bạn đang tìm kiếm thông tin thân thiện với bệnh nhân?

Enmetazobactam trên PillFYI

Cấu trúc

Dữ liệu nhanh

Công thức: C11H14N4O5S

Liên kết ngoài

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.